Cite

    Xavier Sáez-Llorens et al.. “Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.” Lancet infectious diseases, vol. 18, no. 2, 2018, pp. 162–170. http://access.bl.uk/ark:/81055/vdc_100056542758.0x00000a